The emergence of drug transporter-mediated multidrug resistance to cancer chemotherapy

DOI: 10.1021/mp200261n
Molecular Pharmaceutics, 2011, 8, 1996-2011.

#	Paper	IF	Citations
175	Chemotherapy and dietary phytochemical agents. **2012**, 2012, 282570		143
174	Tumor cycling hypoxia induces chemoresistance in glioblastoma multiforme by upregulating the expression and function of ABCB1. **2012**, 14, 1227-38		63
173	Involvement of ABCB1 and ABCC1 transporters in sea urchin Echinometra lucunter fertilization. **2012**, 79, 861-9		5
172	The future of nanomedicine: Promises and limitations. **2012**, 39, 99-104		15
171	OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance. *Biochemical Pharmacology*, **2012**, 84, 766-74	6	20
170	Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin. **2012**, 46, 484-91		20
169	ABC transporters and their role in nucleoside and nucleotide drug resistance. *Biochemical Pharmacology*, **2012**, 83, 1073-83	6	80
168	Influence of the multidrug transporter P-glycoprotein on the intracellular pharmacokinetics of vandetanib. **2013**, 38, 149-57		9
167	Reduction-cleavable polymeric vesicles with efficient glutathione-mediated drug release behavior for reversing drug resistance. *ACS Applied Materials & Interfaces*, **2013**, 5, 10721-30	9.5	46
166	Nanotechnology approaches for personalized treatment of multidrug resistant cancers. **2013**, 65, 1880-95		107
165	Combined p21-activated kinase and farnesyltransferase inhibitor treatment exhibits enhanced anti-proliferative activity on melanoma, colon and lung cancer cell lines. **2013**, 12, 88		8
164	Molecular aspects of cancer cell resistance to chemotherapy. *Biochemical Pharmacology*, **2013**, 85, 1219-26		275
163	Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells. *Biochemical Pharmacology*, **2013**, 85, 325-34	6	56
162	Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1. *Biochemical Pharmacology*, **2013**, 86, 904-13	6	30
161	Curcumin as a multidrug resistance modulator: A quick review. **2013**, 3, 173-176		17
160	Hypoxia alters ocular drug transporter expression and activity in rat and calf models: implications for drug delivery. *Molecular Pharmaceutics*, **2013**, 10, 2350-61	5.6	4
159	Tanshinone-1 induces tumor cell killing, enhanced by inhibition of secondary activation of signaling networks. *Cell Death and Disease*, **2013**, 4, e905	9.8	20

158	In vitro characterization of stem cell-like properties of drug-resistant colon cancer subline. **2013**, 21, 51-7		9
157	bba, a synthetic derivative of 23-hydroxybutulinic acid, reverses multidrug resistance by inhibiting the efflux activity of MRP7 (ABCC10). *PLoS ONE*, **2013**, 8, e74573	3.7	11
156	RND multidrug efflux pumps: what are they good for?. **2013**, 4, 7		126
155	Zurückhaltend einsetzen nach Nutzen-Risiko-Bewertung. **2014**, 17, 32-36		
154	Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance. *Cancers*, **2014**, 6, 1925-52	6.6	46
153	Human ATP-Binding Cassette transporters ABCB1 and ABCG2 confer resistance to CUDC-101, a multi-acting inhibitor of histone deacetylase, epidermal growth factor receptor and human epidermal growth factor receptor 2. *Biochemical Pharmacology*, **2014**, 92, 567-76	6	23
152	1,3,4-Thiadiazole: synthesis, reactions, and applications in medicinal, agricultural, and materials chemistry. **2014**, 114, 5572-610		300
151	Targeted metabolic profiling of pomegranate polyphenols and urolithins in plasma, urine and colon tissues from colorectal cancer patients. **2014**, 58, 1199-211		149
150	The central cavity of ABCB1 undergoes alternating access during ATP hydrolysis. **2014**, 281, 2190-2201		30
149	New oral anticoagulants and the cancer patient. **2014**, 19, 82-93		149
148	3Acetyl tormentic acid reverts MRP1/ABCC1 mediated cancer resistance through modulation of intracellular levels of GSH and inhibition of GST activity. **2014**, 741, 140-9		28
147	Cell-specific expression of uptake transporters--a potential approach for cardiovascular drug delivery devices. *Molecular Pharmaceutics*, **2014**, 11, 665-72	5.6	4
146	Multidrug resistance in cancer or inefficacy of neuroactive agents: innovative strategies to inhibit or circumvent the active efflux transporters selectively. **2014**, 19, 1563-71		23
145	Overexpression of human ABCB1 in cancer cells leads to reduced activity of GSK461364, a specific inhibitor of polo-like kinase 1. *Molecular Pharmaceutics*, **2014**, 11, 3727-36	5.6	16
144	The pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapy. *Acta Pharmaceutica Sinica B*, **2014**, 4, 105-11	15.5	34
143	Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance. *Molecules*, **2014**, 19, 13848-77	4.8	83
142	ABCG2 gene amplification and expression in esophageal cancer cells with acquired adriamycin resistance. **2014**, 9, 1299-304		21
141	Can antibodydrug conjugates bypass multidrug resistance of cancer cells?. **2015**, 106-118		1

140	Label-free isolation of a prostate cancer cell among blood cells and the single-cell measurement of drug accumulation using an integrated microfluidic chip. **2015**, 9, 064104		25
139	Elevated STAT3 Signaling-Mediated Upregulation of MMP-2/9 Confers Enhanced Invasion Ability in Multidrug-Resistant Breast Cancer Cells. *International Journal of Molecular Sciences*, **2015**, 16, 24772-90	6.3	34
138	Intracellular targeted co-delivery of shMDR1 and gefitinib with chitosan nanoparticles for overcoming multidrug resistance. *International Journal of Nanomedicine*, **2015**, 10, 7045-56	7.3	9
137	A novel mathematical model describing adaptive cellular drug metabolism and toxicity in the chemoimmune system. *PLoS ONE*, **2015**, 10, e0115533	3.7	6
136	Thioredoxin 1 upregulates FOXO1 transcriptional activity in drug resistance in ovarian cancer cells. **2015**, 1852, 395-405		27
135	Acquisition of docetaxel resistance in breast cancer cells reveals upregulation of ABCB1 expression as a key mediator of resistance accompanied by discrete upregulation of other specific genes and pathways. **2015**, 36, 4327-38		28
134	The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. **2015**, 18, 1-17		463
133	Drug-induced liver injury: Interactions between drug properties and host factors. **2015**, 63, 503-14		231
132	Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance. **2015**, 9, 1169-85		57
131	Single peptide ligand-functionalized uniform hollow mesoporous silica nanoparticles achieving dual-targeting drug delivery to tumor cells and angiogenic blood vessel cells. *International Journal of Nanomedicine*, **2015**, 10, 1855-67	7.3	24
130	Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro. **2015**, 76, 105-16		22
129	Influence of multidrug resistance and drug transport proteins on chemotherapy drug metabolism. **2015**, 11, 795-809		45
128	Overcoming Resistance to Targeted Therapies in Cancer. **2015**, 42, 896-908		31
127	Human ATP-Binding Cassette Transporter ABCB1 Confers Resistance to Volasertib (BI 6727), a Selective Inhibitor of Polo-like Kinase 1. *Molecular Pharmaceutics*, **2015**, 12, 3885-95	5.6	24
126	Modulators of the human ABCC2: hope from natural sources?. **2015**, 7, 2041-63		12
125	Dinaciclib, a cyclin-dependent kinase inhibitor, is a substrate of human ABCB1 and ABCG2 and an inhibitor of human ABCC1 in vitro. *Biochemical Pharmacology*, **2015**, 98, 465-72	6	23
124	The critical role of bisphosphonates to target bone cancer metastasis: an overview. *Journal of Drug Targeting*, **2015**, 23, 1-15	5.4	57
123	Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance. *Journal of Controlled Release*, **2015**, 198, 1-9	11.7	95

122	TPGS-stabilized NaYbF4:Er upconversion nanoparticles for dual-modal fluorescent/CT imaging and anticancer drug delivery to overcome multi-drug resistance. **2015**, 40, 107-16		157
121	Noncoding RNAs in Therapeutic Resistance of Cancer. **2016**, 927, 265-95		5
120	Enhanced cytotoxicity of nitidine against camptothecin-resistant A549 cells. **2016**, 3, 33-40		1
119	Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations. **2016**, 35, 56		18
118	Osimertinib (AZD9291) Attenuates the Function of Multidrug Resistance-Linked ATP-Binding Cassette Transporter ABCB1 in Vitro. *Molecular Pharmaceutics*, **2016**, 13, 2117-25	5.6	30
117	Nanotechnology for cancer therapy: Invading the mechanics of cancer. **2016**, 395-470		1
116	MiR-106b~25 cluster regulates multidrug resistance in an ABC transporter-independent manner via downregulation of EP300. **2016**, 35, 1170-8		21
115	Current evidence for cancer stem cells in gastrointestinal tumors and future research perspectives. **2016**, 107, 54-71		3
114	Acryloylphenylcarboxamides: A New Class of Breast Cancer Resistance Protein (ABCG2) Modulators. **2016**, 11, 2422-2435		11
113	Improving the Intracellular Drug Concentration in Lung Cancer Treatment through the Codelivery of Doxorubicin and miR-519c Mediated by Porous PLGA Microparticle. *Molecular Pharmaceutics*, **2016**, 13, 3925-3933	5.6	30
112	Glutathione-dependent micelles based on carboxymethyl chitosan for delivery of doxorubicin. **2016** , 27, 1824-1840		5
111	An outline of main factors of drug resistance influencing cancer therapy. **2016**, 28, 457-464		13
110	Gold Nanoantenna-Mediated Photothermal Drug Delivery from Thermosensitive Liposomes in Breast Cancer. *ACS Omega*, **2016**, 1, 234-243	3.9	53
109	The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells. **2016**, 17, 442		21
108	Optimization of Acryloylphenylcarboxamides as Inhibitors of ABCG2 and Comparison with Acryloylphenylcarboxylates. **2016**, 11, 2547-2558		11
107	New anticoagulants in cancer patient treatments. *Anti-Cancer Drugs*, **2016**, 27, 832-8	2.4	2
106	A novel hybrid drug between two potent anti-tubulin agents as a potential prolonged anticancer approach. **2016**, 91, 50-63		6
105	NF-B signaling plays irreplaceable roles in cisplatin-induced bladder cancer chemoresistance and tumor progression. **2016**, 48, 225-34		29

104	Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase. *Molecular Pharmaceutics*, **2016**, 13, 784-94	5.6	27
103	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. *Cancer Letters*, **2016**, 370, 153-64	9.9	459
102	Synergistic effects of negative-charged nanoparticles assisted by ultrasound on the reversal multidrug resistance phenotype in breast cancer cells. **2017**, 34, 448-457		10
101	Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance. **2017**, 31, 15-30		186
100	Overexpression of ATP-Binding Cassette Subfamily G Member 2 Confers Resistance to Phosphatidylinositol 3-Kinase Inhibitor PF-4989216 in Cancer Cells. *Molecular Pharmaceutics*, **2017**, 14, 2368-2377	5.6	7
99	Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: In vitro and in vivo study. *Cancer Letters*, **2017**, 396, 145-154	9.9	39
98	Augmenter of liver regeneration potentiates doxorubicin anticancer efficacy by reducing the expression of ABCB1 and ABCG2 in hepatocellular carcinoma. **2017**, 97, 1400-1411		6
97	Tyrphostin RG14620 selectively reverses ABCG2-mediated multidrug resistance in cancer cell lines. *Cancer Letters*, **2017**, 409, 56-65	9.9	14
96	Augmentation of Anticancer Drug Efficacy in Murine Hepatocellular Carcinoma Cells by a Peripherally Acting Competitive N-Methyl-d-aspartate (NMDA) Receptor Antagonist. *Journal of Medicinal Chemistry*, **2017**, 60, 9885-9904	8.3	16
95	Alpha-Mangostin Reverses Multidrug Resistance by Attenuating the Function of the Multidrug Resistance-Linked ABCG2 Transporter. *Molecular Pharmaceutics*, **2017**, 14, 2805-2814	5.6	12
94	Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro. *Biochemical Pharmacology*, **2018**, 154, 10-17	6	29
93	Cross-Linking of Thiolated Paclitaxel-Oligo(p-phenylene vinylene) Conjugates Aggregates inside Tumor Cells Leads to "Chemical Locks" That Increase Drug Efficacy. **2018**, 30, 1704888		42
92	Synthesis, cytotoxicity and structure-activity relationship of indolizinoquinolinedione derivatives as DNA topoisomerase IB catalytic inhibitors. *European Journal of Medicinal Chemistry*, **2018**, 152, 195-207	6.8	7
91	Knockout of a P-glycoprotein gene increases susceptibility to abamectin and emamectin benzoate in Spodoptera exigua. **2018**, 27, 36-45		36
90	Venous thromboembolic events in lymphoma patients: Actual relationships between epidemiology, mechanisms, clinical profile and treatment. **2018**, 32, 144-158		9
89	Influence of the ABCB1 polymorphisms on the response to Taxane-containing chemotherapy: a systematic review and meta-analysis. **2018**, 81, 315-323		2
88	Multivalency: Key Feature in Overcoming Drug Resistance with a Cleavable Cell-Penetrating Peptide-Doxorubicin Conjugate. **2018**, 24, 355-367		0
87	One-pot synthesis of biodegradable polydopamine-doped mesoporous silica nanocomposites (PMSNs) as pH-sensitive targeting drug nanocarriers for synergistic chemo-photothermal therapy.. **2018**, 8, 37433-37440		13

86	Through oxaliplatin resistance induction in colorectal cancer cells, increasing ABCB1 level accompanies decreasing level of miR-302c-5p, miR-3664-5p and miR-129-5p. *Biomedicine and Pharmacotherapy*, **2018**, 108, 1070-1080	7.5	22
85	Discovery, Synthesis, and Evaluation of Oxynitidine Derivatives as Dual Inhibitors of DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1), and Potential Antitumor Agents. *Journal of Medicinal Chemistry*, **2018**, 61, 9908-9930	8.3	30
84	Broad targeting of triptolide to resistance and sensitization for cancer therapy. *Biomedicine and Pharmacotherapy*, **2018**, 104, 771-780	7.5	32
83	Novel insights into the effect of folate–albumin binding on the transport of ascorbic acid as an anticancer agent: chemometric analysis based on combined spectroscopic and electrochemical studies. **2018**, 42, 11031-11045		1
82	Why Differentiation Therapy Sometimes Fails: Molecular Mechanisms of Resistance to Retinoids. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	29
81	SIS3, a specific inhibitor of Smad3 reverses ABCB1- and ABCG2-mediated multidrug resistance in cancer cell lines. *Cancer Letters*, **2018**, 433, 259-272	9.9	12
80	Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines. *Biochemical Pharmacology*, **2018**, 155, 316-325	6	13
79	The positive inotropic agent DPI-201106 selectively reverses ABCB1-mediated multidrug resistance in cancer cell lines. *Cancer Letters*, **2018**, 434, 81-90	9.9	5
78	Magnetic polymeric nanoassemblies for magnetic resonance imaging-combined cancer theranostics. *International Journal of Nanomedicine*, **2018**, 13, 4263-4281	7.3	7
77	Recent advances in the treatment and prevention of venous thromboembolism in cancer patients: role of the direct oral anticoagulants and their unique challenges. **2019**, 8,		9
76	Verapamil delivery systems on the basis of mesoporous ZSM-5/KIT-6 and ZSM-5/SBA-15 polymer nanocomposites as a potential tool to overcome MDR in cancer cells. **2019**, 142, 460-472		5
75	Regulating intracellular ROS signal by a dual pH/reducing-responsive nanogels system promotes tumor cell apoptosis. *International Journal of Nanomedicine*, **2019**, 14, 5713-5728	7.3	19
74	Rack1 mediates Src binding to drug transporter P-glycoprotein and modulates its activity through regulating Caveolin-1 phosphorylation in breast cancer cells. *Cell Death and Disease*, **2019**, 10, 394	9.8	8
73	Synthesis and biological evaluation of 5-aminoethyl benzophenanthridone derivatives as DNA topoisomerase IB inhibitors. *European Journal of Medicinal Chemistry*, **2019**, 178, 81-92	6.8	8
72	Avapritinib: A Selective Inhibitor of KIT and PDGFR that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines. *Molecular Pharmaceutics*, **2019**, 16, 3040-3052	5.6	28
71	Marine Spirotetronates: Biosynthetic Edifices That Inspire Drug Discovery. *Marine Drugs*, **2019**, 17,	6	9
70	Colchicine Binding Site Agent DJ95 Overcomes Drug Resistance and Exhibits Antitumor Efficacy. *Molecular Pharmacology*, **2019**, 96, 73-89	4.3	12
69	The antitumor activity of CYB-L10, a human topoisomerase IB catalytic inhibitor. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2019**, 34, 818-822	5.6	3

68	Small Molecule Chemosensitizing Agents: Polo-Like Kinase 1 (Plk1), BRAF and Janus Kinase (JAK) Inhibitors. **2019**, 169-185		
67	Silencing the OCT4-PG1 pseudogene reduces OCT-4 protein levels and changes characteristics of the multidrug resistance phenotype in chronic myeloid leukemia. *Molecular Biology Reports*, **2019**, 46, 1873-1884	2.8	7
66	Delineation of proapoptotic signaling of anthracene-shelled ML metallacapsules and their synergistic activity with curcumin in cisplatin-sensitive and resistant tumor cell lines. *Investigational New Drugs*, **2019**, 37, 1117-1126	4.3	2
65	Novel 2-(5-Imino-5-isoquinolones[3,4-]quinoxalin-7-ylmethyl)-benzonitrile () and Other Related Derivatives Targeting Colon Cancer Cells: Syntheses and in Vitro Models. *ACS Omega*, **2019**, 4, 3205-3212	3.9	1
64	The FLT3 inhibitor midostaurin selectively resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents. *Cancer Letters*, **2019**, 445, 34-44	9.9	20
63	The epigallocatechin gallate derivative Y reverses drug resistance mediated by the ABCB1 transporter both and. *Acta Pharmaceutica Sinica B*, **2019**, 9, 316-323	15.5	11
62	Genomics of antibiotic-resistance prediction in Pseudomonas aeruginosa. *Annals of the New York Academy of Sciences*, **2019**, 1435, 5-17	6.5	37
61	The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs. *International Journal of Molecular Sciences*, **2019**, 21,	6.3	6
60	Bruton's Tyrosine Kinase (BTK) Inhibitor RN486 Overcomes ABCB1-Mediated Multidrug Resistance in Cancer Cells. *Frontiers in Cell and Developmental Biology*, **2020**, 8, 865	5.7	12
59	Bruton's Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C3. *Cancers*, **2020**, 12,	6.6	5
58	Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: A Focus on Transporters and Lysosomal Sequestration. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	12
57	Nanomedicine solutions to intricate physiological-pathological barriers and molecular mechanisms of tumor multidrug resistance. *Journal of Controlled Release*, **2020**, 323, 483-501	11.7	6
56	Erdafitinib Resensitizes ABCB1-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs. *Cancers*, **2020**, 12,	6.6	10
55	Stable Chitosan-Based Nanoparticles Using Polyphosphoric Acid or Hexametaphosphate for Tandem Ionotropic/Covalent Crosslinking and Subsequent Investigation as Novel Vehicles for Drug Delivery. *Frontiers in Bioengineering and Biotechnology*, **2020**, 8, 4	5.8	41
54	Sitravatinib Sensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs. *Cancers*, **2020**, 12,	6.6	12
53	Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs. *Journal of Natural Products*, **2020**, 83, 1461-1472	4.9	15
52	Discovery of Potent Inhibitors against P-Glycoprotein-Mediated Multidrug Resistance Aided by Late-Stage Functionalization of a 2-(4-(Pyridin-2-yl)phenoxy)pyridine Analogue. *Journal of Medicinal Chemistry*, **2020**, 63, 5458-5476	8.3	15
51	Inhibition of glycosphingolipid biosynthesis reverts multidrug resistance by differentially modulating ABC transporters in chronic myeloid leukemias. *Journal of Biological Chemistry*, **2020**, 295, 6457-6471	5.4	15

50	Kanglaite enhances the efficacy of cisplatin in suppression of hepatocellular carcinoma via inhibiting CKLF1 mediated NF-B pathway and regulating transporter mediated drug efflux. *Journal of Ethnopharmacology*, **2021**, 264, 113388	5	6
49	Emerging need of advanced drug delivery systems in cancer. **2021**, 27-36		2
48	Overexpression of Human ABCB1 and ABCG2 Reduces the Susceptibility of Cancer Cells to the Histone Deacetylase 6-Specific Inhibitor Citarinostat. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	2
47	Nanomedicines for combating multidrug resistance of cancer. *Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology*, **2021**, 13, e1715	9.2	5
46	Multidrug Resistance in Mammals and Fungi-From MDR to PDR: A Rocky Road from Atomic Structures to Transport Mechanisms. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	11
45	Drug-resistant cancer cell-derived exosomal EphA2 promotes breast cancer metastasis via the EphA2-Ephrin A1 reverse signaling. *Cell Death and Disease*, **2021**, 12, 414	9.8	7
44	Hybrid Drugs-A Strategy for Overcoming Anticancer Drug Resistance?. *Molecules*, **2021**, 26,	4.8	11
43	Prospective Drug Candidates as Human Multidrug Transporter ABCG2 Inhibitors: an In Silico Drug Discovery Study. *Cell Biochemistry and Biophysics*, **2021**, 79, 189-200	3.2	11
42	Transporter associated with antigen processing 1 (TAP1) expression and prognostic analysis in breast, lung, liver, and ovarian cancer. *Journal of Molecular Medicine*, **2021**, 99, 1293-1309	5.5	7
41	The third-generation EGFR inhibitor almonertinib (HS-10296) resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs. *Biochemical Pharmacology*, **2021**, 188, 114516	6	4
40	The reversal of chemotherapy-induced multidrug resistance by nanomedicine for cancer therapy. *Journal of Controlled Release*, **2021**, 335, 1-20	11.7	18
39	Branebrutinib (BMS-986195), a Bruton's Tyrosine Kinase Inhibitor, Resensitizes P-Glycoprotein-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Agents. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 699571	5.7	0
38	Silicane Derivative Increases Doxorubicin Efficacy in an Ovarian Carcinoma Mouse Model: Fighting Drug Resistance. *ACS Applied Materials & Interfaces*, **2021**, 13, 31355-31370	9.5	2
37	pH-sensitive and charge-reversal Daunorubicin-conjugated polymeric micelles for enhanced cancer therapy. *Journal of Applied Polymer Science*, **2022**, 139, 51535	2.9	2
36	The Second-Generation PIM Kinase Inhibitor TP-3654 Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	0
35	Prostate cancer and microfluids. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 455-470	2.8	1
34	Emerging indocyanine green-integrated nanocarriers for multimodal cancer therapy: a review. *Nanoscale Advances*, **2021**, 3, 3332-3352	5.1	6
33	Multidrug Resistance in Cancer: A Tale of ABC Drug Transporters. *Resistance To Targeted Anti-cancer Therapeutics*, **2013**, 1-34	0.3	5

32	Doxorubicin induces apoptosis in Jurkat cells by mitochondria-dependent and mitochondria-independent mechanisms under normoxic and hypoxic conditions. *Anti-Cancer Drugs*, **2015**, 26, 583-98	2.4	17
31	ABCC1 is related to the protection of the distal nephron against hyperosmolality and high sodium environment: possible implications for cancer chemotherapy. *PLoS ONE*, **2013**, 8, e68049	3.7	3
30	Pinellia pedatisecta agglutinin targets drug resistant K562/ADR leukemia cells through binding with sarcolemmal membrane associated protein and enhancing macrophage phagocytosis. *PLoS ONE*, **2013**, 8, e74363	3.7	13
29	Selected ABCB1, ABCB4 and ABCC2 polymorphisms do not enhance the risk of drug-induced hepatotoxicity in a Spanish cohort. *PLoS ONE*, **2014**, 9, e94675	3.7	15
28	ABCB1 and ABCC11 confer resistance to eribulin in breast cancer cell lines. *Oncotarget*, **2016**, 7, 70011-70027	3.3	23
27	Derivatives of 6-cinnamamido-quinoline-4-carboxamide impair lysosome function and induce apoptosis. *Oncotarget*, **2016**, 7, 38078-38090	3.3	11
26	Role of membrane-embedded drug efflux ABC transporters in the cancer chemotherapy. *Oncology Reviews*, **2020**, 14, 448	4.3	16
25	The Overexpression of ABCG2 Reduces the Efficacy of Volasertib (BI 6727) and GSK641364 in Human S1-M1-80 Colon Carcinoma Cells. *Journal of Cancer Research Updates*, **2014**, 3, 108-116	1	1
24	Nanotherapeutics in Multidrug Resistance. **2013**, 389-412		
23	Inhibition of glycosphingolipid biosynthesis reverts multidrug resistance by differential modulation of ABC transporters on chronic myeloid leukemias.		
22	Bosutinib reduces the efficacy of Dasatinib in triple-negative breast cancer cell lines. *Anticancer Research*, **2014**, 34, 1629-35	2.3	5
21	Triptolide reduces proliferation and enhances apoptosis in drug-resistant human oral cancer cells. *International Journal of Clinical and Experimental Pathology*, **2019**, 12, 1204-1213	1.4	2
20	MY-5445, a phosphodiesterase type 5 inhibitor, resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to cytotoxic anticancer drugs. *American Journal of Cancer Research*, **2020**, 10, 164-178	4.4	4
19	Ellagic acid as a potent anti-cancer drug: A comprehensive review on in vitro, in vivo, in silico and drug delivery studies. *Biotechnology and Applied Biochemistry*, **2021**,	2.8	1
18	Poloxamer-linked prodrug of a topoisomerase I inhibitor SN22 shows efficacy in models of high-risk neuroblastoma with primary and acquired chemoresistance.. *FASEB Journal*, **2022**, 36, e22213	0.9	0
17	Overexpression of ABCB1 Associated With the Resistance to the KRAS-G12C Specific Inhibitor ARS-1620 in Cancer Cells.. *Frontiers in Pharmacology*, **2022**, 13, 843829	5.6	1
16	Tumor Targeted Polymer Nanoparticles Co-loaded with Docetaxel and siCCAT2 for Combination Therapy of Lung Cancer.. *Journal of Drug Targeting*, **2021**, 1-26	5.4	1
15	Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel.. *European Journal of Medicinal Chemistry*, **2022**, 233, 114231	6.8	0

14	The multi-targeted tyrosine kinase inhibitor SKLB610 resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs. *Biomedicine and Pharmacotherapy*, **2022**, 149, 112922	7.5	
13	Table_1.DOC. **2020**,		
12	P-glycoprotein Mediates Resistance to the Anaplastic Lymphoma Kinase Inhiitor Ensartinib in Cancer Cells.. *Cancers*, **2022**, 14,	6.6	2
11	On-target inhibition of Cryptosporidium parvum by nitazoxanide (NTZ) and paclitaxel (PTX) validated using a novel MDR1-transgenic host cell model and algorithms to quantify on/off-target rates.		
10	The WD repeat-containing protein 5 (WDR5) antagonist WDR5-0103 restores the efficacy of cytotoxic drugs in multidrug-resistant cancer cells overexpressing ABCB1 or ABCG2. **2022**, 154, 113663		1
9	Novel lectin-based chimeric antigen receptors target Gb3-positive tumour cells. **2022**, 79,		1
8	Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma.		0
7	Thiosemicarbazones and selected tyrosine kinase inhibitors synergize in pediatric solid tumors: NDRG1 upregulation and impaired prosurvival signaling in neuroblastoma cells. 13,		0
6	Characterization of a Potent, Selective, and Safe Inhibitor, Ac15(Az8)2, in Reversing Multidrug Resistance Mediated by Breast Cancer Resistance Protein (BCRP/ABCG2). **2022**, 23, 13261		0
5	Nanomaterials loaded with Quercetin as an advanced tool for cancer treatment. **2022**, 103938		0
4	Shikonin enhances chemosensitivity of oral cancer through □catenin pathway.		0
3	On-target inhibition of Cryptosporidium parvum by nitazoxanide (NTZ) and paclitaxel (PTX) validated using a novel MDR1-transgenic host cell model and algorithms to quantify the effect on the parasite target. **2023**, 17, e0011217		0
2	Drug-tolerant persister B-cell precursor acute lymphoblastic leukemia cells.		0
1	Novel Benzo Five-Membered Heterocycle Derivatives as P-Glycoprotein Inhibitors: Design, Synthesis, Molecular Docking, and Anti-Multidrug Resistance Activity.		0